Anterix (ATEX) executive sells 91K shares after exercising stock options
Rhea-AI Filing Summary
Anterix Inc. Chief Regulatory & Communications Officer Christopher Guttman-McCabe reported a combination of option exercises and share sales in Anterix common stock. On June 15, 2026, he exercised stock options to acquire a total of 122,852 common shares at strike prices between $25.75 and $49.39 per share.
On the same date, he executed open-market sales totaling 91,437 common shares at weighted average prices ranging from about $81.32 to $84.29 per share, across multiple price ranges noted in the footnotes. Following these transactions, one reported entry shows he directly owned 77,807 common shares. The filing also states that the option shares involved in these exercises were fully vested.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
16 txns
Insider
Guttman-McCabe Christopher
Role
Chief Reg & Comm Officer
Sold
91,437 shs ($7.54M)
Approx. gross sale proceeds
$7.54M
Approx. exercise cost
$4.60M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 11,750 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 50,876 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 6,715 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 25,511 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,750 | $25.75 | $303K |
| Exercise | Common Stock | 8,000 | $32.50 | $260K |
| Exercise | Common Stock | 50,876 | $34.40 | $1.75M |
| Exercise | Common Stock | 20,000 | $37.42 | $748K |
| Exercise | Common Stock | 6,715 | $42.14 | $283K |
| Exercise | Common Stock | 25,511 | $49.39 | $1.26M |
| Sale | Common Stock | 35,321 | $81.3236 | $2.87M |
| Sale | Common Stock | 26,411 | $82.2727 | $2.17M |
| Sale | Common Stock | 16,381 | $83.7233 | $1.37M |
| Sale | Common Stock | 13,324 | $84.2898 | $1.12M |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 shares (Direct);
Common Stock — 77,807 shares (Direct)
Footnotes (5)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.98 to $81.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.06 to $84.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.07 to $84.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5. The option shares are fully vested.
Key Figures
Shares sold: 91,437 shares
Options exercised: 122,852 shares
Sale prices: $81.3236–$84.2898/share
+4 more
7 metrics
Shares sold
91,437 shares
Open-market sales of Anterix common stock on June 15, 2026
Options exercised
122,852 shares
Common shares acquired via option exercises on June 15, 2026
Sale prices
$81.3236–$84.2898/share
Weighted average prices for reported sale tranches
Strike prices
$25.75–$49.39/share
Exercise prices for the stock options converted
Shares held after
77,807 shares
Direct common stock holdings shown after reported sales
Largest option block
50,876 shares at $34.40
Single option grant exercised into common stock
Net share direction
-91,437 shares
Net of reported buy/sell activity (sale vs. purchase codes)
Key Terms
open-market sale, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
fully vested financial
"The option shares are fully vested."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Anterix (ATEX) report for Christopher Guttman-McCabe?
Anterix reported that Chief Regulatory & Communications Officer Christopher Guttman-McCabe exercised stock options for 122,852 common shares and sold 91,437 common shares in open-market transactions on June 15, 2026, at various weighted average sale prices around the low-to-mid $80s.
What stock options did the Anterix (ATEX) executive exercise in this Form 4?
He exercised options covering 122,852 Anterix common shares at strike prices of $25.75, $32.50, $34.40, $37.42, $42.14, and $49.39 per share. The filing notes that the option shares were fully vested at the time of exercise, converting derivative rights into common stock.
Were the Anterix (ATEX) insider sales executed in single or multiple trades?
The sales were executed in multiple trades. The Form 4 footnotes state that each reported weighted average price reflects numerous individual transactions within specific price ranges, and that full trade-by-trade detail is available from the reporting person upon request.
What is the role of the insider involved in the Anterix (ATEX) Form 4 filing?
The insider is Christopher Guttman-McCabe, who serves as Anterix Inc.’s Chief Regulatory & Communications Officer. His Form 4 reports both the exercise of fully vested stock options and subsequent open-market sales of Anterix common stock on June 15, 2026.